Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Delivery of recombinant adeno-associated virus-mediated human tissue kallikrein for therapy of chronic renal failure in rats.

Tu L, Xu X, Wan H, Zhou C, Deng J, Xu G, Xiao X, Chen Y, Edin ML, Voltz JW, Zeldin DC, Wang DW.

Hum Gene Ther. 2008 Apr;19(4):318-30. doi: 10.1089/hum.2007.138.

2.

Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways.

Yuan G, Deng J, Wang T, Zhao C, Xu X, Wang P, Voltz JW, Edin ML, Xiao X, Chao L, Chao J, Zhang XA, Zeldin DC, Wang DW.

Endocrinology. 2007 May;148(5):2016-26. Epub 2007 Feb 1.

3.
4.

Delivery of AAV2-CYP2J2 protects remnant kidney in the 5/6-nephrectomized rat via inhibition of apoptosis and fibrosis.

Zhao G, Tu L, Li X, Yang S, Chen C, Xu X, Wang P, Wang DW.

Hum Gene Ther. 2012 Jul;23(7):688-99. doi: 10.1089/hum.2011.135. Epub 2012 Mar 29.

PMID:
22260463
5.

Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries.

Wang T, Li H, Zhao C, Chen C, Li J, Chao J, Chao L, Xiao X, Wang DW.

Gene Ther. 2004 Sep;11(17):1342-50.

PMID:
15175642
6.

Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress.

Zhang JJ, Bledsoe G, Kato K, Chao L, Chao J.

Kidney Int. 2004 Aug;66(2):722-32.

7.

Recombinant adeno-associated virus-mediated human kallikrein gene therapy protects against hypertensive target organ injuries through inhibiting cell apoptosis.

Yan JT, Wang T, Wang DW.

Acta Pharmacol Sin. 2009 Sep;30(9):1253-61. doi: 10.1038/aps.2009.114. Epub 2009 Aug 17.

8.

Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat.

Braun C, Kleemann T, Hilgenfeldt U, Riester U, Rohmeiss P, van der Woude FJ.

Kidney Int. 2002 Jun;61(6):2149-56.

9.

Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors.

Kohzuki M, Kanazawa M, Liu PF, Kamimoto M, Yoshida K, Saito T, Yasujima M, Sato T, Abe K.

J Hypertens. 1995 Dec;13(12 Pt 2):1785-90.

PMID:
8903652
10.

Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery.

Bledsoe G, Shen B, Yao Y, Zhang JJ, Chao L, Chao J.

Hum Gene Ther. 2006 May;17(5):545-55.

PMID:
16716111
11.

Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure.

Li P, Ma LL, Xie RJ, Xie YS, Wei RB, Yin M, Wang JZ, Chen XM.

Acta Pharmacol Sin. 2012 May;33(5):644-51. doi: 10.1038/aps.2012.2.

12.

Intramuscular delivery of rAAV-mediated kallikrein gene reduces hypertension and prevents cardiovascular injuries in model rats.

Wang T, Hou LB, Liu ZJ, Wang Y, Chen CL, Xiao X, Wang DW.

Acta Pharmacol Sin. 2007 Dec;28(12):1898-906.

13.

Adenovirus-mediated human tissue kallikrein gene delivery inhibits neointima formation induced by interruption of blood flow in mice.

Emanueli C, Salis MB, Chao J, Chao L, Agata J, Lin KF, Munaò A, Straino S, Minasi A, Capogrossi MC, Madeddu P.

Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1459-66. Erratum in: Arterioscler Thromb Vasc Biol 2000 Nov;20(11):2500.

PMID:
10845858
14.
15.

Recombinant adeno-associated virus-mediated human kallikrein gene therapy prevents high-salt diet-induced hypertension without effect on basal blood pressure.

Yan JT, Wang T, Li J, Xiao X, Wang DW.

Acta Pharmacol Sin. 2008 Jul;29(7):808-14. doi: 10.1111/j.1745-7254.2008.00815.x.

16.

Potassium supplement upregulates the expression of renal kallikrein and bradykinin B2 receptor in SHR.

Jin L, Chao L, Chao J.

Am J Physiol. 1999 Mar;276(3):F476-84. doi: 10.1152/ajprenal.1999.276.3.F476.

PMID:
10070172
17.

Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation.

Li HJ, Yin H, Yao YY, Shen B, Bader M, Chao L, Chao J.

Cardiovasc Res. 2007 Jan 1;73(1):130-42. Epub 2006 Oct 27.

18.

Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats.

Xia CF, Bledsoe G, Chao L, Chao J.

Am J Physiol Renal Physiol. 2005 Sep;289(3):F622-31. Epub 2005 May 10.

19.

Role of tissue kallikrein in prevention and recovery of gentamicin-induced renal injury.

Bledsoe G, Shen B, Yao YY, Hagiwara M, Mizell B, Teuton M, Grass D, Chao L, Chao J.

Toxicol Sci. 2008 Apr;102(2):433-43. doi: 10.1093/toxsci/kfn008. Epub 2008 Jan 27.

PMID:
18227104
20.

ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular receptor activation in diabetic rats.

Allard J, Buléon M, Cellier E, Renaud I, Pecher C, Praddaude F, Conti M, Tack I, Girolami JP.

Am J Physiol Renal Physiol. 2007 Oct;293(4):F1083-92. Epub 2007 Jun 27.

Supplemental Content

Support Center